Loading...
•
Dec 31, 2024
Atricure Q4 2024 Earnings Report
AtriCure reported strong revenue growth in Q4 2024, driven by international expansion and new product launches, despite a net loss.
Key Takeaways
AtriCure, Inc. announced a 16.6% increase in worldwide revenue for the fourth quarter of 2024, reaching $124.3 million. The company reported a net loss of $15.6 million, or $0.33 per share, for the quarter, and positive adjusted EBITDA of $12.7 million.
Worldwide revenue increased by 16.6% year-over-year to $124.3 million in Q4 2024.
U.S. revenue grew by 14.4% to $101.6 million, while international revenue surged by 27.7% to $22.7 million.
The company launched several new devices, including cryoSPHERE®+, cryoSPHERE MAX™, AtriClip® FLEX-Mini™™, and EnCompass® clamp.
Gross profit for Q4 2024 was $92.6 million, with a gross margin of 74.5%.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
AtriCure projects full year 2025 revenue to be between $517 million and $527 million, with positive adjusted EBITDA expected to be between $42 million and $44 million. Adjusted loss per share is anticipated to be in the range of $0.57 to $0.64, with modest cash flow generation.
Positive Outlook
- Projected full year 2025 revenue growth to $517 million - $527 million.
- Expected increase in positive adjusted EBITDA to $42 million - $44 million for FY 2025.
- Anticipated modest cash flow generation for the full year 2025.
- Continued market penetration and physician adoption.
- Ongoing new product launches across key franchises.
Challenges Ahead
- Projected adjusted loss per share of $0.57 to $0.64 for FY 2025.
- Potential impacts from rising healthcare costs.
- Risks associated with competition from existing and new products.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...